enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Andrew Left - Wikipedia

    en.wikipedia.org/wiki/Andrew_Left

    Left's 2015 report on Valeant Pharmaceuticals (later known as Bausch Health) accused the company of channel stuffing [38] and using sham transactions to inflate drug sales. Left's initial report focused on an investigation launched by Senator Bernie Sanders and Representative Elijah Cummings that examined Valeant's business model of massively ...

  3. Bausch Health - Wikipedia

    en.wikipedia.org/wiki/Bausch_Health

    [59] [60] In October 2015, the company's Bausch & Lomb division acquired Doctor's Allergy Formula for an undisclosed sum. [61] On October 21, 2015, Citron Research founder Andrew Left, a short seller of Valeant shares, published claims that Valeant recorded false sales of products to specialty pharmacy Philidor Rx Services and its

  4. US indicts Andrew Left in $16 million stock market ... - AOL

    www.aol.com/news/us-indicts-andrew-left-16...

    A federal grand jury has indicted prominent activist short seller Andrew Left on multiple counts of securities fraud for a long-running $16 million market manipulation scheme, the U.S. Justice ...

  5. J. Michael Pearson - Wikipedia

    en.wikipedia.org/wiki/J._Michael_Pearson

    J. Michael Pearson (born 1959) is a Canadian American [1] pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International [2] [3] after being ousted in the aftermath of a report on pharmaceutical pricing published by Citron Research in April 2016.

  6. Bausch Health to spin-off eye care business - AOL

    www.aol.com/bausch-health-spin-off-eye-110806842...

    Canadian drugmaker Bausch Health Companies Inc said on Thursday it would spin-off its eye care unit Bausch + Lomb into a separate publicly listed company. Bausch Health, previously known as ...

  7. Left's Citron hedge fund posts 43% gain in first year - AOL

    www.aol.com/news/lefts-citron-hedge-fund-posts...

    Andrew Left, who has long targeted companies that he thinks are over-valued through his work at Citron Research, told investors on Monday that his new hedge fund returned 43% after fees in 2019 ...

  8. Bausch and Lomb's dealmaking CEO Brent Saunders: No ... - AOL

    www.aol.com/finance/bausch-lombs-dealmaking-ceo...

    Bausch Health Companies owns 88.4% of Bausch and Lomb. ... The company forecast its dry-eye business to break $1 billion in sales this year, up from $916 million in 2024.

  9. ISTA Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Ista_Pharmaceuticals

    ISTA Pharmaceuticals, Inc., was a US-based pharmaceutical company that specialized in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. [1] ISTA was acquired by Bausch & Lomb, an eye care company, on March 26, 2012. [2]